{
  "id": 17082469,
  "title": "Thyrocare Q2 Profit Slips 68% YoY To ₹15 Cr Due To ₹45 Cr Exceptional Expense",
  "url": "https://urgent.news/2026/10/29/thyrocare-q2-profit-slips-68-yoy-to-15-cr-due-to-45-cr-exceptional",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-29T15:37:34.000Z",
  "source": {
    "name": "Inc42",
    "slug": "inc42",
    "url": "https://inc42.com/buzz/thyrocare-q2-profit-slips-68-yoy-to-%e2%82%b915-cr-due-to-%e2%82%b945-cr-exceptional-expense/"
  },
  "original_language": "en",
  "account": "Thyrocare, a company backed by PharmEasy, experienced a significant 68.2% drop in net profit for the September quarter (Q2 FY27) to ₹15.2 Cr, compared to ₹47.8 Cr in the same period last year. The decline was even more pronounced, with a 70% drop from ₹51.3 Cr in the previous quarter. The main reason for this financial setback was an exceptional impairment loss of approximately ₹45 Cr on its investment in the radiology and diagnostic-imaging subsidiary, Nueclear Healthcare Limited (NHL). The company's board approved the sale of its entire stake in the subsidiary to Trovera Healthcare on September 21, generating about ₹141.4 Cr. This sale was aimed at allowing Thyrocare to concentrate on its Pathology business, which has a stronger growth potential, higher margins, and better return on capital employed (ROCE).\n\nDespite the sharp decline in profit, Thyrocare's operating revenue rose by 25% year-over-year (YoY) and 13% quarter-over-quarter (QoQ) to ₹270.8 Cr. Diagnostic testing services revenue grew by 26% YoY to ₹256.7 Cr, while revenue from imaging services fell by 5% to ₹13.6 Cr. Including other income of ₹3.6 Cr, the total income for the quarter amounted to ₹274.4 Cr. Expenses for the quarter were ₹196.6 Cr, and the tax expense was ₹18.4 Cr. Excluding the impairment charge, the company's profit before tax increased by around 25% YoY to ₹77.8 Cr. Thyrocare's EBITDA for the quarter also grew by 25% YoY to ₹89.3 Cr.\n\nOn the operational side, the company processed 61.6 Mn tests in the quarter, a 27% YoY increase. Customer complaints declined by 24% YoY to 2.9 per Mn tests. Looking ahead, Thyrocare is venturing into specialty diagnostics, starting with allergy testing and genomics, with plans to expand its specialty test portfolio.",
  "summary": "PharmEasy-backed Thyrocare’s net profit for the September quarter (Q2 FY27) slumped 68.2% year-on-year (YoY) to ₹15.2 Cr from ₹47.8 Cr…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}